ANTX
AN2 Therapeutics, Inc.- Healthcare
- Biotechnology
- $134M market cap
Forecast run · Oct 29, 2026Upside rank 819 of 3,186
Model Signal
ForecastQ Daily Probabilities
37.9%
70.3%
38.7%
Analyst Consensus
Recommendation2.38/5 Buy
Last price$3.55
Price target$9.00
Implied move+153.5%
Analysts8
ForecastQ Portfolios
ANTX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.